Titre :

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients

Auteur(s) :

Reichert, Constance [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Baldini, Capucine [Auteur]
Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse [AMMICa]
Institut Gustave Roussy [IGR]
Mezghani, Sarah [Auteur]
Institut Curie [Paris]
Maubec, Eve [Auteur]
Université Sorbonne Paris Nord
Hôpital Avicenne [AP-HP]
Longvert, Christine [Auteur]
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie [BECCOH]
Université Paris-Saclay
Hôpital Ambroise Paré [AP-HP]
Mortier, Laurent [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
Quereux, Gaëlle [Auteur]
Centre d’Investigation Clinique de Nantes [CIC Nantes]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Immunology and New Concepts in ImmunoTherapy [INCIT]
Jannic, Arnaud [Auteur]
Service d'immunologie clinique et maladies infectieuses [Hôpitaux universitaires CHU Henri Mondor]
Machet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
de Quatrebarbes, Julie [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Nardin, Charlée [Auteur]
Etablissement français du sang [Bourgogne-Franche-Comté] [EFS BFC]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) [RIGHT]
Beneton, Nathalie [Auteur]
Centre Hospitalier Le Mans (CH Le Mans)
Amini Adle, Mona [Auteur]
Centre Léon Bérard [Lyon]
Funck-Brentano, Elisa [Auteur]
Université Paris-Saclay
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie [BECCOH]
Hôpital Ambroise Paré [AP-HP]
Descamps, Vincent [Auteur]
Université Paris Cité [UPCité]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Hachon, Lorry [Auteur]
CIC Hôpital Bichat
Malissen, Nausicaa [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Baroudjian, Barouyr [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Hopital Saint-Louis [AP-HP] [AP-HP]
Brunet-Possenti, Florence [Auteur]
Université Paris Cité [UPCité]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]

Titre de la revue :

Cancers

Pagination :

4330

Éditeur :

MDPI

Date de publication :

2023-09

ISSN :

2072-6694

Mot(s)-clé(s) en anglais :

anti-CTLA-4
anti-PD-1
elderly
immune checkpoint inhibitors
melanoma
nonagenarian
octogenarian

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Data regarding elderly melanoma patients treated with anti-PD-1 or anti-CTLA-4 antibodies are in favor of tolerability outcomes that are similar to those of younger counterparts. However, there are very few studies focusing ...
Lire la suite >Data regarding elderly melanoma patients treated with anti-PD-1 or anti-CTLA-4 antibodies are in favor of tolerability outcomes that are similar to those of younger counterparts. However, there are very few studies focusing on elderly patients receiving nivolumab combined with ipilimumab (NIVO + IPI). Here, we ask what are the current prescribing patterns of NIVO + IPI in the very elderly population and analyze the tolerance profile. This French multicenter retrospective study was conducted on 60 melanoma patients aged 80 years and older treated with NIVO + IPI between January 2011 and June 2022. The mean age at first NIVO + IPI administration was 83.7 years (range: 79.3–93.3 years). Fifty-five patients (92%) were in good general condition and lived at home. Two dosing regimens were used: NIVO 1 mg/kg + IPI 3 mg/kg Q3W (NIVO1 + IPI3) in 27 patients (45%) and NIVO 3 mg/kg + IPI 1 mg/kg Q3W (NIVO3 + IPI1) in 33 patients (55%). NIVO + IPI was a first-line treatment in 39 patients (65%). The global prevalence of immune-related adverse events was 63% (38/60), with 27% (16/60) being of grade 3 or higher. Grade ≥ 3 adverse events were less frequent in patients treated with NIVO3 + IPI1 compared with those treated with NIVO1 + IPI3 (12% versus 44%, p = 0.04). In conclusion, the prescribing patterns of NIVO + IPI in very elderly patients are heterogeneous in terms of the dosing regimen and line of treatment. The safety profile of NIVO + IPI is reassuring; whether or not the low-dose regimen NIVO3 + IPI1 should be preferred over NIVO1 + IPI3 in patients aged 80 years or older remains an open question.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189

Source :

Harvested from HAL